Cargando…
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
LKB1/STK11 is a multitasking tumour suppressor kinase. Germline inactivating mutations of the gene are responsible for the Peutz-Jeghers hereditary cancer syndrome. It is also somatically inactivated in approximately 30% of non-small-cell lung cancer (NSCLC). Here, we report that LKB1/KRAS mutant NS...
Autores principales: | Mahoney, C L, Choudhury, B, Davies, H, Edkins, S, Greenman, C, Haaften, G van, Mironenko, T, Santarius, T, Stevens, C, Stratton, M R, Futreal, P A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2634725/ https://www.ncbi.nlm.nih.gov/pubmed/19165201 http://dx.doi.org/10.1038/sj.bjc.6604886 |
Ejemplares similares
-
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer
por: Ruder, Dennis, et al.
Publicado: (2018) -
PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data
por: Greenman, Chris D., et al.
Publicado: (2010) -
Dysregulation of mTOR activity through LKB1 inactivation
por: Zhou, Wei, et al.
Publicado: (2013) -
Elucidating the role of Lkb1 and mTOR in adipose tissue
por: Xu, Ziye, et al.
Publicado: (2018) -
TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model
por: Meraz, Ismail M., et al.
Publicado: (2022)